The FirstTake - CAR-T, early-stage breast cancer and OX40

In this episode editors Virginia Li, Michael Flanagan and Simon King talk about notable new disclosures in the field of allogeneic CART therapy, look at the approval of Eli Lilly’s Verzenio for early stage breast cancer, gauge whether early data for drugs targeting OX40 could mark a paradigm shift in the treatment of moderate to severe atopic dermatitis and discuss rumours about the next FDA commissioner.